Literature DB >> 6189577

Chemotherapy of breast cancer. A general overview.

I C Henderson.   

Abstract

The symptoms of metastatic breast cancer may be effectively palliated with chemotherapeutic agents in most breast cancer patients. In addition, the survival of many of these patients may be prolonged, sometimes dramatically, but none can be cured with available regimens once metastases are established. The introduction of chemotherapy as an adjuvant immediately following mastectomy or radiotherapy may have curative potential. Studies performed at the Instituto Nazionale Tumori in Milan, Italy have now been reported with six years of follow-up; 43% of premenopausal women treated with mastectomy only are disease-free and 62% are alive. In contrast 60% of the premenopausal women treated with both mastectomy and one year of CMF are disease-free (P less than 0.001) and 78% are alive (P = 0.02). The precise role of chemotherapy for postmenopausal women without node metastasis is still controversial. In addition it is not yet clear which drug regimens are best or whether the differences will still be apparent after 20 years of follow-up. Premature acceptance of currently available chemotherapy regimens may ultimately slow down the rate of development of new programs truly capable of curing patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6189577     DOI: 10.1002/1097-0142(19830615)51:12+<2553::aid-cncr2820511329>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 3.  Patterns of metastasis and natural courses of breast carcinoma.

Authors:  Y T Lee
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

4.  Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines.

Authors:  J Bellmunt; S Morales; M Navarro; L A Solé
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 5.  The current and future place of vinorelbine in cancer therapy.

Authors:  E Cvitkovic; J Izzo
Journal:  Drugs       Date:  1992       Impact factor: 9.546

6.  Individual chemosensitivity of in vitro proliferating mammary and ovarian carcinoma cells in comparison to clinical results of chemotherapy.

Authors:  M Albrecht; W E Simon; F Hölzel
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

Review 7.  Current status of Taxotere (docetaxel) as a new treatment in breast cancer.

Authors:  P Fumoleau; B Chevallier; P Kerbrat; V Dieras; N Azli; M Bayssas; M Van Glabbeke
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

Review 8.  The actin depolymerizing factor (ADF)/cofilin signaling pathway and DNA damage responses in cancer.

Authors:  Chun-Yuan Chang; Jyh-Der Leu; Yi-Jang Lee
Journal:  Int J Mol Sci       Date:  2015-02-13       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.